Trial Profile
A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2022
Price :
$35
*
At a glance
- Drugs Caffeine (Primary) ; Capmatinib (Primary) ; Midazolam (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 12 Sep 2022 Results published in the British Journal of Clinical Pharmacology
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 24 Aug 2017 Planned End Date changed from 5 Jul 2017 to 12 Sep 2017.